Restore Medical is a clinical-stage MedTech company based in Or Yehuda, Israel, developing novel minimally invasive transcatheter therapies for heart failure. Its core product is a transcatheter device intended to restore hemodynamic balance and improve clinical outcomes for patients with limited effective treatment options. The company reports promising long-term safety and efficacy from its European feasibility study, including meaningful improvements in ventricular reverse remodeling, hemodynamic performance, and patient functional capacity. Restore Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2024. The $23M Series B will fund completion of the ongoing European feasibility study and support the launch of a U.S.-based clinical study. The company was co-founded by Stephen Bellomo (CTO), Dr. Elchanan Bruckheimer (Medical Director), and Aaron Feldman, began operations within Peregrine Ventures' Incentive Incubator, and is led by CEO Gilad Marom.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2025